{"id":17766,"date":"2026-11-17T00:10:07","date_gmt":"2026-11-17T00:10:07","guid":{"rendered":"https:\/\/atlasemhematologia.com.br\/blog\/?p=17766"},"modified":"2026-11-09T00:32:00","modified_gmt":"2026-11-09T00:32:00","slug":"mielofibrose-primaria-2","status":"publish","type":"post","link":"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/","title":{"rendered":"Mielofibrose Prim\u00e1ria"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">A mielofibrose prim\u00e1ria \u00e9 uma neoplasia mieloproliferativa cr\u00f4nica caracterizada pela substitui\u00e7\u00e3o progressiva do par\u00eanquima hematopo\u00e9tico medular por tecido fibr\u00f3tico, com desenvolvimento de hematopoese extramedular em \u00f3rg\u00e3os como ba\u00e7o e f\u00edgado. \u00c9 a menos comum das neoplasias mieloproliferativas cl\u00e1ssicas, mas a de maior morbidade e mortalidade. O hemograma reflete de forma caracter\u00edstica o comprometimento da arquitetura medular e a tentativa compensat\u00f3ria de produ\u00e7\u00e3o celular fora da medula. Reconhecer o padr\u00e3o leucoeritrobl\u00e1stico com dacri\u00f3citos \u00e9 uma das contribui\u00e7\u00f5es mais relevantes da hematologia morfol\u00f3gica para o diagn\u00f3stico dessa condi\u00e7\u00e3o.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/eventos.atlasemhematologia.com.br\/listadeesperatimeblogatlas\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1030\" height=\"276\" src=\"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/03\/BANNER-BLOG-ATLAS-1030x276.png\" alt=\"\" class=\"wp-image-17314\" srcset=\"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/03\/BANNER-BLOG-ATLAS-1030x276.png 1030w, https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/03\/BANNER-BLOG-ATLAS-300x80.png 300w, https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/03\/BANNER-BLOG-ATLAS-768x206.png 768w, https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/03\/BANNER-BLOG-ATLAS-1536x411.png 1536w, https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/03\/BANNER-BLOG-ATLAS-2048x549.png 2048w\" sizes=\"(max-width: 1030px) 100vw, 1030px\" \/><\/a><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">Hemograma na mielofibrose: anemia progressiva e padr\u00e3o leukoeritrobl\u00e1stico<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">O hemograma na mielofibrose prim\u00e1ria apresenta anemia normoc\u00edtica normocr\u00f4mica de intensidade progressiva, resultante da substitui\u00e7\u00e3o do par\u00eanquima medular por fibrose e da eritropoese ineficaz. A reticulocitose \u00e9 vari\u00e1vel e frequentemente inadequada para o grau de anemia. A leucocitose com desvio \u00e0 esquerda escalonado \u00e9 comum nas fases iniciais, refletindo a libera\u00e7\u00e3o de formas imaturas pela medula comprometida. A contagem de plaquetas pode estar elevada no in\u00edcio, tornando-se progressivamente reduzida com a evolu\u00e7\u00e3o da fibrose.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">O padr\u00e3o leucoeritrobl\u00e1stico, definido pela presen\u00e7a simult\u00e2nea de eritroblastos e c\u00e9lulas mieloides imaturas no sangue perif\u00e9rico, \u00e9 o achado mais caracter\u00edstico da mielofibrose prim\u00e1ria. Resulta da ruptura da barreira hematol\u00f3gica normal, que na medula fibr\u00f3tica n\u00e3o consegue mais reter adequadamente as c\u00e9lulas imaturas. A associa\u00e7\u00e3o desse padr\u00e3o com esplenomegalia progressiva e sintomas constitucionais, como fadiga, suores noturnos e perda ponderal, \u00e9 altamente sugestiva de mielofibrose.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" width=\"848\" height=\"848\" src=\"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/11\/image-11.png\" alt=\"\" class=\"wp-image-17790\" style=\"aspect-ratio:1;width:532px;height:auto\" srcset=\"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/11\/image-11.png 848w, https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/11\/image-11-80x80.png 80w, https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/11\/image-11-300x300.png 300w, https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/11\/image-11-768x768.png 768w\" sizes=\"(max-width: 848px) 100vw, 848px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">Dacri\u00f3citos: a c\u00e9lula que aponta para a medula comprometida<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Os dacri\u00f3citos, hem\u00e1cias em forma de gota de l\u00e1grima, s\u00e3o o poiquil\u00f3cito mais associado \u00e0 mielofibrose prim\u00e1ria. Resultam da deforma\u00e7\u00e3o mec\u00e2nica sofrida pelas hem\u00e1cias ao atravessar o tecido fibr\u00f3tico e as trab\u00e9culas \u00f3sseas espessadas da medula comprometida. Sua presen\u00e7a no esfrega\u00e7o de sangue perif\u00e9rico, em n\u00famero significativo e associada ao padr\u00e3o leucoeritrobl\u00e1stico, \u00e9 um sinal morfol\u00f3gico de alto valor diagn\u00f3stico que deve ser reportado com destaque no laudo.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cabe destacar que os dacri\u00f3citos n\u00e3o s\u00e3o exclusivos da mielofibrose. Eles tamb\u00e9m aparecem em outras condi\u00e7\u00f5es com infiltra\u00e7\u00e3o ou fibrose medular, como met\u00e1stases de tumores s\u00f3lidos, anemia de c\u00e9lulas falciformes e talassemia grave. O contexto cl\u00ednico e a associa\u00e7\u00e3o com outros achados do hemograma s\u00e3o indispens\u00e1veis para a interpreta\u00e7\u00e3o adequada desse poiquil\u00f3cito.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Confirma\u00e7\u00e3o diagn\u00f3stica e papel do laborat\u00f3rio<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">O diagn\u00f3stico definitivo da mielofibrose prim\u00e1ria requer bi\u00f3psia de medula \u00f3ssea com demonstra\u00e7\u00e3o de fibrose reticul\u00ednica ou col\u00e1gena grau 2 ou 3, associada \u00e0 pesquisa de muta\u00e7\u00f5es nos genes JAK2, CALR ou MPL, presentes em aproximadamente 90% dos casos. O hemograma e o esfrega\u00e7o, entretanto, s\u00e3o os exames que geram a suspeita inicial e que orientam o encaminhamento para avalia\u00e7\u00e3o hematol\u00f3gica especializada.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">O laborat\u00f3rio tem papel cont\u00ednuo no monitoramento da mielofibrose: a progress\u00e3o da anemia, a piora da trombocitopenia e o surgimento de blastos em n\u00famero crescente no sangue perif\u00e9rico s\u00e3o sinais de transforma\u00e7\u00e3o para leucemia aguda, complica\u00e7\u00e3o que ocorre em 10% a 20% dos pacientes ao longo do seguimento. O hemograma seriado \u00e9, portanto, uma ferramenta de vigil\u00e2ncia ativa nessa condi\u00e7\u00e3o.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Refer\u00eancias<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">OLIVEIRA, Larissa Santana; ALCANTARA, Thiago Ruan de Lima. <em>Atlas em hematologia: um guia visual para a identifica\u00e7\u00e3o de c\u00e9lulas sangu\u00edneas<\/em>. 1. ed. Salvador: Oxente, 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DIA, Teresa D\u00e9bora Gon\u00e7alves Meio. Manual para avalia\u00e7\u00e3o de prolifera\u00e7\u00f5es e neoplasias mieloides nos servi\u00e7os de anatomia patol\u00f3gica. 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">TEFFERI, Ayalew. Myelofibrosis with myeloid metaplasia. <strong>New England Journal of Medicine<\/strong>, v. 342, n. 17, p. 1255-1265, 2000.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GUERRER, Marcela Idalia et al. Hematopoese extramedular como achado incidental em exame de imagem na emerg\u00eancia: relato de caso. <strong>Rev. m\u00e9d. Paran\u00e1<\/strong>, p. 58-61, 2019.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A mielofibrose prim\u00e1ria \u00e9 uma neoplasia mieloproliferativa cr\u00f4nica caracterizada pela substitui\u00e7\u00e3o progressiva do par\u00eanquima hematopo\u00e9tico medular por tecido fibr\u00f3tico, com desenvolvimento de hematopoese extramedular em \u00f3rg\u00e3os como ba\u00e7o e f\u00edgado. \u00c9 a menos comum das neoplasias mieloproliferativas cl\u00e1ssicas, mas a de maior morbidade e mortalidade. O hemograma reflete de forma caracter\u00edstica o comprometimento da arquitetura [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":17789,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pagelayer_contact_templates":[],"_pagelayer_content":"","footnotes":""},"categories":[18],"tags":[],"class_list":["post-17766","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-doencas-hematologicas"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mielofibrose Prim\u00e1ria - Blog - Atlas em Hematologia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mielofibrose Prim\u00e1ria - Blog - Atlas em Hematologia\" \/>\n<meta property=\"og:description\" content=\"A mielofibrose prim\u00e1ria \u00e9 uma neoplasia mieloproliferativa cr\u00f4nica caracterizada pela substitui\u00e7\u00e3o progressiva do par\u00eanquima hematopo\u00e9tico medular por tecido fibr\u00f3tico, com desenvolvimento de hematopoese extramedular em \u00f3rg\u00e3os como ba\u00e7o e f\u00edgado. \u00c9 a menos comum das neoplasias mieloproliferativas cl\u00e1ssicas, mas a de maior morbidade e mortalidade. O hemograma reflete de forma caracter\u00edstica o comprometimento da arquitetura [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog - Atlas em Hematologia\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-17T00:10:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/11\/2710-BLOG.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"EQUIPE SOCIAL MEDIA INML\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"EQUIPE SOCIAL MEDIA INML\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/\"},\"author\":{\"name\":\"EQUIPE SOCIAL MEDIA INML\",\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/#\/schema\/person\/196f68c9c85dd34becfda2cfd3e084a2\"},\"headline\":\"Mielofibrose Prim\u00e1ria\",\"datePublished\":\"2026-11-17T00:10:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/\"},\"wordCount\":674,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/#organization\"},\"image\":{\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/11\/2710-BLOG.png\",\"articleSection\":[\"DOEN\u00c7AS HEMATOL\u00d3GICAS\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/\",\"url\":\"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/\",\"name\":\"Mielofibrose Prim\u00e1ria - Blog - Atlas em Hematologia\",\"isPartOf\":{\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/11\/2710-BLOG.png\",\"datePublished\":\"2026-11-17T00:10:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#primaryimage\",\"url\":\"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/11\/2710-BLOG.png\",\"contentUrl\":\"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/11\/2710-BLOG.png\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/atlasemhematologia.com.br\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mielofibrose Prim\u00e1ria\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/#website\",\"url\":\"https:\/\/atlasemhematologia.com.br\/blog\/\",\"name\":\"Blog - Atlas em Hematologia\",\"description\":\"Blog - Atlas em Hematologia\",\"publisher\":{\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/atlasemhematologia.com.br\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/#organization\",\"name\":\"Blog - Atlas em Hematologia\",\"url\":\"https:\/\/atlasemhematologia.com.br\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2025\/09\/Logo-TA-Horizontal-1-scaled.png\",\"contentUrl\":\"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2025\/09\/Logo-TA-Horizontal-1-scaled.png\",\"width\":2560,\"height\":886,\"caption\":\"Blog - Atlas em Hematologia\"},\"image\":{\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/atlasemhematologia.com.br\/blog\/#\/schema\/person\/196f68c9c85dd34becfda2cfd3e084a2\",\"name\":\"EQUIPE SOCIAL MEDIA INML\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/8da9a6de167aede6c9e15d1dcbb7e3640bcc86e9eb8d65df6aea6e20baddf53f?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/8da9a6de167aede6c9e15d1dcbb7e3640bcc86e9eb8d65df6aea6e20baddf53f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/8da9a6de167aede6c9e15d1dcbb7e3640bcc86e9eb8d65df6aea6e20baddf53f?s=96&d=mm&r=g\",\"caption\":\"EQUIPE SOCIAL MEDIA INML\"},\"url\":\"https:\/\/atlasemhematologia.com.br\/blog\/author\/social-media\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mielofibrose Prim\u00e1ria - Blog - Atlas em Hematologia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/","og_locale":"pt_BR","og_type":"article","og_title":"Mielofibrose Prim\u00e1ria - Blog - Atlas em Hematologia","og_description":"A mielofibrose prim\u00e1ria \u00e9 uma neoplasia mieloproliferativa cr\u00f4nica caracterizada pela substitui\u00e7\u00e3o progressiva do par\u00eanquima hematopo\u00e9tico medular por tecido fibr\u00f3tico, com desenvolvimento de hematopoese extramedular em \u00f3rg\u00e3os como ba\u00e7o e f\u00edgado. \u00c9 a menos comum das neoplasias mieloproliferativas cl\u00e1ssicas, mas a de maior morbidade e mortalidade. O hemograma reflete de forma caracter\u00edstica o comprometimento da arquitetura [&hellip;]","og_url":"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/","og_site_name":"Blog - Atlas em Hematologia","article_published_time":"2026-11-17T00:10:07+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/11\/2710-BLOG.png","type":"image\/png"}],"author":"EQUIPE SOCIAL MEDIA INML","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"EQUIPE SOCIAL MEDIA INML","Est. tempo de leitura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#article","isPartOf":{"@id":"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/"},"author":{"name":"EQUIPE SOCIAL MEDIA INML","@id":"https:\/\/atlasemhematologia.com.br\/blog\/#\/schema\/person\/196f68c9c85dd34becfda2cfd3e084a2"},"headline":"Mielofibrose Prim\u00e1ria","datePublished":"2026-11-17T00:10:07+00:00","mainEntityOfPage":{"@id":"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/"},"wordCount":674,"commentCount":0,"publisher":{"@id":"https:\/\/atlasemhematologia.com.br\/blog\/#organization"},"image":{"@id":"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#primaryimage"},"thumbnailUrl":"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/11\/2710-BLOG.png","articleSection":["DOEN\u00c7AS HEMATOL\u00d3GICAS"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/","url":"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/","name":"Mielofibrose Prim\u00e1ria - Blog - Atlas em Hematologia","isPartOf":{"@id":"https:\/\/atlasemhematologia.com.br\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#primaryimage"},"image":{"@id":"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#primaryimage"},"thumbnailUrl":"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/11\/2710-BLOG.png","datePublished":"2026-11-17T00:10:07+00:00","breadcrumb":{"@id":"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#primaryimage","url":"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/11\/2710-BLOG.png","contentUrl":"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2026\/11\/2710-BLOG.png","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/atlasemhematologia.com.br\/blog\/mielofibrose-primaria-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/atlasemhematologia.com.br\/blog\/"},{"@type":"ListItem","position":2,"name":"Mielofibrose Prim\u00e1ria"}]},{"@type":"WebSite","@id":"https:\/\/atlasemhematologia.com.br\/blog\/#website","url":"https:\/\/atlasemhematologia.com.br\/blog\/","name":"Blog - Atlas em Hematologia","description":"Blog - Atlas em Hematologia","publisher":{"@id":"https:\/\/atlasemhematologia.com.br\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atlasemhematologia.com.br\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/atlasemhematologia.com.br\/blog\/#organization","name":"Blog - Atlas em Hematologia","url":"https:\/\/atlasemhematologia.com.br\/blog\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/atlasemhematologia.com.br\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2025\/09\/Logo-TA-Horizontal-1-scaled.png","contentUrl":"https:\/\/atlasemhematologia.com.br\/blog\/wp-content\/uploads\/2025\/09\/Logo-TA-Horizontal-1-scaled.png","width":2560,"height":886,"caption":"Blog - Atlas em Hematologia"},"image":{"@id":"https:\/\/atlasemhematologia.com.br\/blog\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/atlasemhematologia.com.br\/blog\/#\/schema\/person\/196f68c9c85dd34becfda2cfd3e084a2","name":"EQUIPE SOCIAL MEDIA INML","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/8da9a6de167aede6c9e15d1dcbb7e3640bcc86e9eb8d65df6aea6e20baddf53f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8da9a6de167aede6c9e15d1dcbb7e3640bcc86e9eb8d65df6aea6e20baddf53f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8da9a6de167aede6c9e15d1dcbb7e3640bcc86e9eb8d65df6aea6e20baddf53f?s=96&d=mm&r=g","caption":"EQUIPE SOCIAL MEDIA INML"},"url":"https:\/\/atlasemhematologia.com.br\/blog\/author\/social-media\/"}]}},"_links":{"self":[{"href":"https:\/\/atlasemhematologia.com.br\/blog\/wp-json\/wp\/v2\/posts\/17766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atlasemhematologia.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atlasemhematologia.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atlasemhematologia.com.br\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/atlasemhematologia.com.br\/blog\/wp-json\/wp\/v2\/comments?post=17766"}],"version-history":[{"count":1,"href":"https:\/\/atlasemhematologia.com.br\/blog\/wp-json\/wp\/v2\/posts\/17766\/revisions"}],"predecessor-version":[{"id":17791,"href":"https:\/\/atlasemhematologia.com.br\/blog\/wp-json\/wp\/v2\/posts\/17766\/revisions\/17791"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/atlasemhematologia.com.br\/blog\/wp-json\/wp\/v2\/media\/17789"}],"wp:attachment":[{"href":"https:\/\/atlasemhematologia.com.br\/blog\/wp-json\/wp\/v2\/media?parent=17766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atlasemhematologia.com.br\/blog\/wp-json\/wp\/v2\/categories?post=17766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atlasemhematologia.com.br\/blog\/wp-json\/wp\/v2\/tags?post=17766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}